Renal Biomarkers Market By Biomarker Type (Functional Biomarker (Serum Creatinine, Serum Cystatin C, and Urine Albumin) and Up-regulated Protein (Neutrophil Gelatinase-associated Lipocalin (NGAL), Kidney Injury Molecule-1, and INTERLEUKIN-18)), By Diagnostic Technique (Enzyme-linked Immunosorbent Assay, Particle-enhanced Turbidimetric Immunoassay (PETIA), Colorimetric Assay, Chemiluminescent Enzyme Immunoassay (CLIA), and Others), By End-user (Hospital, Diagnostic Laboratory, and Other End Users), and By Region - Trends, Analysis and Forecast till 2034

Renal Biomarker Market accounted for USD 1084.5 Million in 2020 and is estimated to be USD 2230.2 Million by 2030 and is anticipated to register a CAGR of 7.50%.

A biomarker is a measurable pointer of a specific biological state and it gives a reflection of the stage of, or the presence of, a disease. Renal biomarkers can be used clinically to screen, monitor or diagnose certain kidney-related diseases. They are also used to guide molecularly targeted therapy or to assess therapeutic response.

Growing prevalence of various kidney-related diseases among individuals globally is the major factor driving the growth of the renal biomarkers market. Chronic kidney disease (CKD) is a disorder that causes reduced kidney function over some time. It may develop over many years and lead to end-stage kidney disease (ESRD). It has become a massive public health issue that endures rising. As per the data published by the Global Burden of Disease Study, kidney disease was the 12th-most common cause of death, estimating for 1.1 million deaths globally in 2015. CKD mortality increased by 31.7% over the past decade, making it one of the fastest rising major causes of death, along with dementia and diabetes. It ranked as the 17th leading cause of global years loss of life, which was an increase of 18.4% since 2005.

This is in contrast to other noncommunicable diseases, like chronic obstructive pulmonary disease and cardiovascular disease, where the global year's loss of life fell during the same period. The high prevalence of high blood pressure and diabetes, which are the leading causes of renal diseases, and rapid technological advancements in the field of genetics. Advancements in the field of genetic technology over the last decade have enlightened people's knowledge regarding genetic regulatory pathways related to renal biomarkers. Genetics analyses have become essential in clinical practice and research, due to rapid advances in genomic technologies. Moreover, with the development of computer technology, renal biomarkers testing has become extensively accessible and feasible to perform, even in small-sized laboratories, thus boosting the growth of the target market. However, issues related to regulatory and reimbursement systems may hamper the growth of the target market over the forecast period. Nevertheless, recent advances in genetics have created lucrative growth opportunities for the target market. These rapid developments in genetics led to the expansion of more advanced renal biomarkers for treating kidney diseases, which ultimately boosts the target market.

Renal biomarkers market is segmented based on biomarker type, diagnostic technique, end-user, and region.

Based on biomarker type, the renal biomarkers market is segmented into functional biomarker and up-regulated protein. Functional biomarker segment is further divided into serum creatinine, serum cystatin C, and urine albumin. Up-regulated protein segment is further divided into neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1, and INTERLEUKIN-18. Based on diagnostic technique, the target market is segmented into enzyme-linked immunosorbent assay, particle-enhanced turbidimetric immunoassay (PETIA), colorimetric assay, chemiluminescent enzyme immunoassay (CLIA), and others. Based on end-user, the global market is classified into a hospital, diagnostic laboratory, and other end users.

Based on the region the renal biomarkers market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America and Europe are estimated to remain the dominant markets for renal biomarkers owing to robust economic growth, high expenditure on health care, and high awareness and acceptance of novel diagnostic methods in the regions. Changing demographics in developing economies, such as, India, China, Brazil, and South Africa are projected to provide high growth opportunities for the renal biomarkers market. Private and public health care expenditure in these countries is projected to witness high growth, which in turn, is likely to boost the growth of these markets. The rise in global per capita income, coupled with robust growth in health care expenditure drives the renal biomarkers market. Improving government reimbursement programs and health care infrastructure in the developed, as well as developing countries, are likely to provide growth opportunities to the target market over the forecast period.

Renal Biomarkers Market, By Biomarker Type:

• Functional Biomarker

• Serum Creatinine
• Serum Cystatin C
• Urine Albumin

• Up-regulated Protein

• Neutrophil Gelatinase-associated Lipocalin (NGAL)
• Kidney Injury Molecule-1
• INTERLEUKIN-18

Renal Biomarkers Market, By Diagnostic Technique:

• Enzyme-linked Immunosorbent Assay
• Particle-enhanced Turbidimetric Immunoassay (PETIA)
• Colorimetric Assay
• Chemiluminescent Enzyme Immunoassay (CLIA)
• Others

Renal Biomarkers Market, By End-user:

• Hospital
• Diagnostic Laboratory
• Other End Users

Renal Biomarkers Market, By Region:

• North America
  • Asia Pacific
    • Asia Pacific Renal Biomarkers Market, By Biomarker Type
    • Asia Pacific Renal Biomarkers Market, By Diagnostic Technique
    • Asia Pacific Renal Biomarkers Market, By End-user
    • Asia Pacific Renal Biomarkers Market, By Country
      • China
      • India
      • Japan
      • South Korea
      • Rest of Asia Pacific
  • Europe
    • Europe Renal Biomarkers Market, By Biomarker Type
    • Europe Renal Biomarkers Market, By Diagnostic Technique
    • Europe Renal Biomarkers Market, By End-user
    • Europe Renal Biomarkers Market, By Country
      • Germany
      • UK
      • France
      • Russia
      • Italy
      • Rest of Europe
  • North America Renal Biomarkers Market, By Biomarker Type
  • North America Renal Biomarkers Market, By Diagnostic Technique
  • North America Renal Biomarkers Market, By End-user
  • North America Renal Biomarkers Market, By Country
    • The U.S.
    • Canada
• Latin America
  • Latin America Renal Biomarkers Market, By Biomarker Type
  • Latin America Renal Biomarkers Market, By Country
    • Rest of Latin America
    • Mexico
    • Brazil
    • Latin America Renal Biomarkers Market, By End-user
    • Latin America Renal Biomarkers Market, By Diagnostic Technique

• Middle East & Africa
  • Middle East & Africa Renal Biomarkers Market, By Biomarker Type
  • Middle East & Africa Renal Biomarkers Market, By Diagnostic Technique
  • Middle East & Africa Renal Biomarkers Market, By End-user
  • Middle East & Africa Renal Biomarkers Market, By Country
    • GCC
    • Israel
    • South Africa
    • Rest of Middle East & Africa

The key players operating the renal biomarkers market involves Abbott Laboratories, BioPorto Diagnostics A/S, F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Pacific Biomarkers, BioMérieux, Beckman Coulter (Danaher Corporation), Randox Laboratories Ltd., and Siemens Healthineers. Prominent players operating in the target market are focusing on strategic partnerships as well as the launching of the products to gain a competitive edge in the target market. For instance, in February 2019, Spark Therapeutics Inc. and Roche declared a definitive merger agreement, which enables Roche to fully acquire Spark Therapeutics at a price of US$ 114.50 per share, in an all-cash transaction.

• Abbott Laboratories
• BioPorto Diagnostics A/S
• F. Hoffmann-La Roche AG
• Thermo Fisher Scientific Inc.
• Pacific Biomarkers
• BioMérieux, Beckman Coulter (Danaher Corporation)
• Randox Laboratories Ltd.
• Siemens Healthineers